• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Complete Remission of Basal Cell Carcinoma Following Treatment With Cemiplimab After 2 Years.

作者信息

Dumann Konstantin, Artz Niklas, Ziemer Mirjana

机构信息

Department of Dermatology, University Hospital Leipzig, Leipzig, Germany.

出版信息

JAMA Dermatol. 2021 Aug 1;157(8):1004-1006. doi: 10.1001/jamadermatol.2021.2206.

DOI:10.1001/jamadermatol.2021.2206
PMID:34232273
Abstract
摘要

相似文献

1
Complete Remission of Basal Cell Carcinoma Following Treatment With Cemiplimab After 2 Years.使用西米普利单抗治疗2年后基底细胞癌完全缓解
JAMA Dermatol. 2021 Aug 1;157(8):1004-1006. doi: 10.1001/jamadermatol.2021.2206.
2
Lasting response after discontinuation of cemiplimab in a patient with locally advanced basal cell carcinoma.局部晚期基底细胞癌患者停用西米普利单抗后的持久反应。
Clin Exp Dermatol. 2021 Dec;46(8):1612-1614. doi: 10.1111/ced.14804. Epub 2021 Jul 29.
3
CorrespondenceMetastatic basal cell carcinoma with neuroendocrine differentiation: complete response to cemiplimab.通信转移性基底细胞癌伴神经内分泌分化：对西米普利单抗完全缓解
Clin Exp Dermatol. 2024 Aug 22;49(9):1060-1062. doi: 10.1093/ced/llae099.
4
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.西妥昔单抗治疗后局部晚期基底细胞癌：一项开放标签、多中心、单臂、2 期临床试验。
Lancet Oncol. 2021 Jun;22(6):848-857. doi: 10.1016/S1470-2045(21)00126-1. Epub 2021 May 14.
5
Digital ischemia triggered by coronavirus disease 2019 in a patient under cemiplimab treatment.一名接受西米普利单抗治疗的患者出现由2019冠状病毒病引发的手指缺血。
Int J Dermatol. 2021 Jan;60(1):e30-e32. doi: 10.1111/ijd.15239. Epub 2020 Oct 11.
6
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.西米普利单抗用于刺猬抑制剂治疗后局部晚期基底细胞癌患者的2期开放标签、多中心、单臂研究：延长随访
J Am Acad Dermatol. 2024 Feb;90(2):414-418. doi: 10.1016/j.jaad.2023.08.111. Epub 2023 Oct 14.
7
Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma.帕博利珠单抗治疗转移性黑色素瘤期间浅表基底细胞癌持续存在。
Eur J Dermatol. 2021 Feb 1;31(1):99-100. doi: 10.1684/ejd.2020.3958.
8
Metastatic basal cell carcinoma with a high tumor mutational burden that achieved complete response with pembrolizumab.具有高肿瘤突变负荷的转移性基底细胞癌，使用帕博利珠单抗治疗后达到完全缓解。
Int J Dermatol. 2023 Feb;62(2):e79-e80. doi: 10.1111/ijd.16245. Epub 2022 May 12.
9
Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study.帕博利珠单抗治疗晚期基底细胞癌：一项研究者发起的概念验证研究。
J Am Acad Dermatol. 2019 Feb;80(2):564-566. doi: 10.1016/j.jaad.2018.08.017. Epub 2018 Aug 24.
10
Neoadjuvant cemiplimab induces durable complete response in locally advanced cutaneous squamous cell carcinoma.新辅助西米普利单抗在局部晚期皮肤鳞状细胞癌中诱导持久完全缓解。
J Eur Acad Dermatol Venereol. 2023 Dec;37(12):e1414-e1416. doi: 10.1111/jdv.19344. Epub 2023 Jul 24.

引用本文的文献

1
Advanced Basal Cell Carcinoma: A Narrative Review on Current Systemic Treatments and the Neoadjuvant Approach.晚期基底细胞癌：关于当前全身治疗及新辅助治疗方法的叙述性综述
J Pers Med. 2025 Jun 1;15(6):226. doi: 10.3390/jpm15060226.
2
Cemiplimab in the treatment of metastatic basal cell carcinoma.西米普利单抗治疗转移性基底细胞癌。
Future Oncol. 2025 Jul;21(16):1999-2005. doi: 10.1080/14796694.2025.2511568. Epub 2025 May 27.
3
PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment.PD-1 和 PD-L1：免疫交响乐的建筑师和癌症治疗免疫疗法突破的推动者。
Front Immunol. 2023 Dec 1;14:1296341. doi: 10.3389/fimmu.2023.1296341. eCollection 2023.
4
Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment.晚期基底细胞癌治疗中的免疫疗法及其时机选择
Dermatol Pract Concept. 2023 Oct 1;13(4):e2023252. doi: 10.5826/dpc.1304a252.
5
Complete response of a large basosquamous carcinoma following treatment with cemiplimab and vismodegib.西妥昔单抗联合维莫非尼治疗巨大基底细胞鳞癌完全缓解 1 例
BMJ Case Rep. 2023 Jul 14;16(7):e251273. doi: 10.1136/bcr-2022-251273.
6
Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response.非黑色素瘤皮肤癌患者中免疫治疗候选者的识别：反应潜在预测因素综述
J Clin Med. 2022 Jun 11;11(12):3364. doi: 10.3390/jcm11123364.
7
New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma.新兴治疗选择用于晚期基底细胞癌和鳞状细胞癌。
Adv Ther. 2022 Mar;39(3):1164-1178. doi: 10.1007/s12325-022-02044-1. Epub 2022 Jan 28.
8
Current Perspectives in the Treatment of Locally Advanced Basal Cell Carcinoma.局部晚期基底细胞癌治疗的现状。
Drug Des Devel Ther. 2022 Jan 14;16:183-190. doi: 10.2147/DDDT.S325852. eCollection 2022.
9
Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes.基底细胞癌亚型中程序性细胞死亡配体 1（PD-L1）和炎症细胞的差异表达。
Arch Dermatol Res. 2022 Oct;314(8):777-786. doi: 10.1007/s00403-021-02289-w. Epub 2021 Oct 13.